All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

D. Hughes; D.A. Hughes; [No Value] All Wales Strategy Group.

All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

D. Hughes
, D.A. Hughes
, [No Value] All Wales Strategy Group.

NHS Wales

Research output: Book/Report › Commissioned report

Original language	English
Publisher	Unknown
Commissioning body	NHS Wales
Edition	2008
Publication status	Published - 1 Jan 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@book{9bda076b871d4f4c92e986c72b2a778c,

title = "All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.",

author = "D. Hughes and D.A. Hughes and \{All Wales Strategy Group.\}, \{[No Value]\}",

year = "2008",

month = jan,

day = "1",

language = "English",

publisher = "Unknown",

edition = "2008",

}

All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age. / Hughes, D.; Hughes, D.A.; All Wales Strategy Group., [No Value].
2008 ed. Unknown, 2008.

Research output: Book/Report › Commissioned report

TY - BOOK

T1 - All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

AU - Hughes, D.

AU - Hughes, D.A.

AU - All Wales Strategy Group., [No Value]

PY - 2008/1/1

Y1 - 2008/1/1

UR - http://www.wales.nhs.uk/sites3/Documents/371/Abacavir%20lamivudine%20(Kivexa)%20FAR%20Final%20For%20Website.pdf

M3 - Commissioned report

BT - All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

PB - Unknown

ER -

All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

UN SDGs

Other files and links

Cite this